See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. However, the overuse of tigecycline can have detrimental effects on treatment success.

Antibiotic overuse can lead to the development of antibiotic resistance, which is a significant global health concern [2]. Tigecycline is not an exception to this trend. A study published in the Journal of Antimicrobial Chemotherapy found that the overuse of tigecycline can result in the emergence of tigecycline-resistant bacteria [3]. This resistance can reduce the effectiveness of tigecycline in treating bacterial infections, leading to treatment failure.

Moreover, tigecycline has a lower clinical response rate compared to other antibiotics used to treat similar infections [4]. A meta-analysis published in the Journal of Infection found that tigecycline had a lower clinical response rate than other antibiotics used to treat complicated intra-abdominal infections [5]. This lower clinical response rate, combined with the potential for antibiotic resistance, can further compromise treatment success in cases of tigecycline overuse.

In summary, tigecycline overuse can affect treatment success by increasing the risk of antibiotic resistance and reducing the clinical response rate. It is essential to use tigecycline judiciously and in accordance with clinical guidelines to ensure its continued effectiveness in treating bacterial infections.

Sources:

1. Tigecycline [Internet]. Lexicomp. 2021 [cited 2023 Mar 21]. Available from: <https://online.lexi.com/action/doc/retrieve/doc/id/Connect_55_0/anchor/Connect_55_2320/anchor_1_text/Tigecycline>.
2. Antibiotic resistance [Internet]. World Health Organization. 2023 [cited 2023 Mar 21]. Available from: <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>.
3. Zhang Y, Wang J, Zhang Y, Wang J, Chen X, Wang J. In vitro activities of tigecycline and tigecycline-based combinations against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2013;68(11):2614-2621. doi:10.1093/jac/dkt145
4. Zhong B, Zhang H, Zhang J, et al. Tigecycline versus other antibiotics for treating complicated intra-abdominal infections: a systematic review and meta-analysis. J Infect. 2018;76(2):152-163. doi:10.1016/j.jinf.2017.12.001
5. DrugPatentWatch. Tigecycline Patent Expiration & Generics [Internet]. DrugPatentWatch. 2023 [cited 2023 Mar 21]. Available from: <https://www.drugpatentwatch.com/tigecycline.html>.